Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faecal loss of vedolizumab and its impact on serum levels and response in ulcerative colitis
2018-002794-21Phase 4Unknown
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of vedolizumab in autoimmune colitis, sponsored by Guy's and St Thomas' NHS Foundation Trust. Primary endpoint: Faecal vedolizumab quantification and correlation with serum levels. Status: unknown.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2018-002794-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002794-21.